Niloufer Khan

2.8k total citations · 1 hit paper
26 papers, 724 citations indexed

About

Niloufer Khan is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Niloufer Khan has authored 26 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 7 papers in Immunology. Recurrent topics in Niloufer Khan's work include Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (6 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Niloufer Khan is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), CAR-T cell therapy research (6 papers) and Cutaneous lymphoproliferative disorders research (6 papers). Niloufer Khan collaborates with scholars based in United States, Italy and Switzerland. Niloufer Khan's co-authors include Shrujal S. Baxi, Deborah Korenstein, Renee L. Gennarelli, Annie Yang, Lindsay Boyce, Ziwei Wang, Mohammad K. Khan, Arun D. Singh, Roger M. Macklis and Alexandru Almasan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Niloufer Khan

23 papers receiving 714 citations

Hit Papers

Immune-related adverse events for anti-PD-1 and anti-PD-L... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    2018 436 citations Shrujal S. Baxi, Annie Yang et al. BMJ profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niloufer Khan United States 8 504 152 139 109 73 26 724
Dimitri Korol Switzerland 16 322 0.6× 103 0.7× 162 1.2× 188 1.7× 104 1.4× 42 742
Akio Kohno Japan 16 264 0.5× 74 0.5× 119 0.9× 201 1.8× 96 1.3× 63 770
Mustafa Oktay Tarhan Türkiye 18 612 1.2× 83 0.5× 228 1.6× 117 1.1× 52 0.7× 63 867
Thomas Fietz Germany 16 413 0.8× 120 0.8× 154 1.1× 88 0.8× 90 1.2× 40 872
Theresa Schwartz United States 14 337 0.7× 173 1.1× 131 0.9× 88 0.8× 125 1.7× 25 731
Mohamed Yassine United States 14 437 0.9× 58 0.4× 148 1.1× 64 0.6× 73 1.0× 33 750
Isabella C. Glitza United States 19 579 1.1× 114 0.8× 319 2.3× 255 2.3× 73 1.0× 46 953
İbrahim Vedat Bayoğlu Türkiye 17 606 1.2× 87 0.6× 268 1.9× 94 0.9× 35 0.5× 75 843
Simon Spazzapan Italy 16 495 1.0× 91 0.6× 246 1.8× 77 0.7× 62 0.8× 60 776
Annie Wong Australia 11 862 1.7× 208 1.4× 274 2.0× 124 1.1× 58 0.8× 20 1.0k

Countries citing papers authored by Niloufer Khan

Since Specialization
Citations

This map shows the geographic impact of Niloufer Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niloufer Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niloufer Khan more than expected).

Fields of papers citing papers by Niloufer Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niloufer Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niloufer Khan. The network helps show where Niloufer Khan may publish in the future.

Co-authorship network of co-authors of Niloufer Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Niloufer Khan. A scholar is included among the top collaborators of Niloufer Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niloufer Khan. Niloufer Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steiner, Raphaël, Liana Nikolaenko, Ranjit Nair, et al.. (2025). Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial. Blood Advances. 9(21). 5556–5563.
2.
Khan, Niloufer, Esther Drill, Alison J. Moskowitz, et al.. (2023). Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma. Blood. 142(Supplement 1). 381–381.
3.
Rosenthal, Allison, Adam DuVall, Justine M. Kahn, & Niloufer Khan. (2023). Disparities in care and outcomes for adolescent and young adult lymphoma patients. SHILAP Revista de lepidopterología. 4(4). 934–939. 4 indexed citations
4.
Khan, Niloufer, et al.. (2022). Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. Journal of Palliative Medicine. 25(6). 958–963.
5.
Landau, Heather, Elizabeth Rodríguez, Allison J. Applebaum, et al.. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(12). 832.e1–832.e7. 5 indexed citations
6.
Johnson, W. Thomas, Nivetha Ganesan, Zachary D. Epstein‐Peterson, et al.. (2021). TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. Blood. 138(Supplement 1). 1367–1367. 2 indexed citations
7.
Khan, Niloufer, Farhad Khimani, Andrei R. Shustov, et al.. (2021). Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.. Journal of Clinical Oncology. 39(15_suppl). 7533–7533. 1 indexed citations
8.
Postow, Michael A., Jessica A. Lavery, Shrujal S. Baxi, et al.. (2020). Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 8(1). e000260–e000260. 34 indexed citations
9.
Thom, Bridgette, Jessica A. Lavery, Shrujal S. Baxi, et al.. (2020). The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. Journal of Psychosocial Oncology. 39(2). 285–293. 29 indexed citations
10.
Khan, Niloufer, Joseph Feliciano, Kerstin Müller, et al.. (2020). Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leukemia & lymphoma. 61(11). 2630–2637. 7 indexed citations
11.
12.
13.
Baxi, Shrujal S., Annie Yang, Renee L. Gennarelli, et al.. (2018). Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 360. k793–k793. 436 indexed citations breakdown →
14.
Khan, Niloufer, Neval Özkaya, Alison J. Moskowitz, Ahmet Doǧan, & Steven M. Horwitz. (2018). Peripheral T-cell lymphoma – are we making progress?. Best Practice & Research Clinical Haematology. 31(3). 306–314. 7 indexed citations
15.
Khan, Niloufer & Alison J. Moskowitz. (2017). Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. Current Hematologic Malignancy Reports. 12(3). 227–233. 4 indexed citations
16.
Khan, Niloufer, Andrew Hantel, Randall W. Knoebel, et al.. (2017). Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia & lymphoma. 58(9). 2127–2133. 18 indexed citations
17.
Christoffersen, P, et al.. (2015). Estimation of Direct Medical Costs Associated with Treatment of Metastatic Melanoma in Switzerland. Value in Health. 18(7). A451–A451. 1 indexed citations
18.
Khan, Niloufer, Mohammad K. Khan, James Bena, Roger M. Macklis, & Arun D. Singh. (2012). Plaque Brachytherapy for Uveal Melanoma: A Vision Prognostication Model. International Journal of Radiation Oncology*Biology*Physics. 84(3). e285–e290. 16 indexed citations
19.
Khan, Niloufer, Mohammad K. Khan, Alexandru Almasan, Arun D. Singh, & Roger M. Macklis. (2011). The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. International Journal of Radiation Oncology*Biology*Physics. 80(3). 645–654. 52 indexed citations
20.
Khan, Niloufer, et al.. (2011). Factors Predictive of Developing Radiation Retinopathy (RR) and Vision Loss following Plaque Brachytherapy for Uveal Melanoma. International Journal of Radiation Oncology*Biology*Physics. 81(2). S295–S296. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dimitri Korol Breakdown of academic impact, for papers by Akio Kohno Breakdown of academic impact, for papers by Mustafa Oktay Tarhan Breakdown of academic impact, for papers by Thomas Fietz Breakdown of academic impact, for papers by Theresa Schwartz Breakdown of academic impact, for papers by Mohamed Yassine Breakdown of academic impact, for papers by Isabella C. Glitza Breakdown of academic impact, for papers by İbrahim Vedat Bayoğlu Breakdown of academic impact, for papers by Simon Spazzapan Breakdown of academic impact, for papers by Annie Wong
Rankless by CCL
2026